Arca
Skip to content
Tools
Tools

ERBB2: Receptor tyrosine-protein kinase erbB-2

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding.

  • Drugs that act on it: 38
  • Approved: 12
  • In phases 1 to 3: 26
  • Sponsors: 26

Who Is On It, and How Far Along

Every drug ChEMBL records acting on ERBB2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Antibody
  • Antibody-drug conjugate
  • Other

Approved12

Phase 37

Phase 212

Phase 17

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • RemeGen Co., Ltd.25%
  • Tianjin Hemay Pharmaceutical Co., Ltd25%
  • ArriVent BioPharma, Inc.13%
  • Black Diamond Therapeutics, Inc.13%
  • Byondis B.V.13%
  • Chengdu SciMount Pharmatech Co., Ltd.13%

Modalities

Drugs on this target by ChEMBL molecule type.

  • Small molecule2258%
  • Antibody616%
  • Antibody-drug conjugate616%
  • Other411%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 28 of 38 act as: Receptor protein-tyrosine kinase erbB-2 inhibitor; the rest name their own mechanism.
TrastuzumabApproved—AntibodyInhibitor—610Boxed warning
PertuzumabApprovedQilu Pharmaceutical (Hainan)AntibodyInhibitor—225Boxed warning
Trastuzumab deruxtecanApprovedChengdu SciMount Pharmatech Co., Ltd.Antibody-drug conjugateBinding agentReceptor protein-tyrosine kinase erbB-2 binding agent186Boxed warning
Trastuzumab emtansineApprovedGeneQuantum Healthcare (Suzhou) Co., Ltd.Antibody-drug conjugateBinding agentReceptor protein-tyrosine kinase erbB-2 binding agent76Boxed warning
TucatinibApprovedPfizerSmall moleculeInhibitor—40—
NeratinibApprovedPuma BiotechnologySmall moleculeInhibitor—33—
AfatinibApprovedArriVent BioPharma, Inc.Small moleculeInhibitor—28—
ZanidatamabApprovedJazz PharmaceuticalsAntibodyInhibitor—27—
LapatinibApprovedTianjin Hemay Pharmaceutical Co., LtdSmall moleculeInhibitor—9Boxed warning
MargetuximabApprovedTerSera TherapeuticsAntibodyInhibitor—2Boxed warning
Dacomitinib anhydrousApprovedPfizerSmall moleculeInhibitor—0—
MasoprocolApprovedUniv Az Cancer CtrSmall moleculeInhibitor—0—
PyrotinibPhase 3RemeGen Co., Ltd.Small moleculeInhibitor—99—
Disitamab vedotinPhase 3RemeGen Co., Ltd.Antibody-drug conjugateBinding agentReceptor tyrosine-protein kinase erbB-2 binding agent89—
KN-026Phase 3Shanghai JMT-Bio Inc.OtherInhibitor—9—
HEMAY-022Phase 3Tianjin Hemay Pharmaceutical Co., LtdOtherInhibitor—1—
Trastuzumab duocarmazinePhase 3Byondis B.V.Antibody-drug conjugateBinding agentReceptor protein-tyrosine kinase erbB-2 binding agent1—
CanertinibPhase 3PfizerSmall moleculeInhibitor—0—
TesevatinibPhase 3SanofiSmall moleculeInhibitor—0—
Anvatabart opadotinPhase 2Zhejiang Medicine Co., Ltd.Antibody-drug conjugateBinding agentReceptor protein-tyrosine kinase erbB-2 binding agent1—
SapitinibPhase 2AstraZeneca PharmaceuticalsSmall moleculeInhibitor—1—
AEE-788Phase 2Novartis PharmaceuticalsSmall moleculeInhibitor—0—
AllitinibPhase 2—Small moleculeInhibitor—0—
BMS-690514Phase 2Bristol-Myers SquibbSmall moleculeInhibitor—0—
CP-724714Phase 2PfizerSmall moleculeInhibitor—0—
ErtumaxomabPhase 2Neovii BiotechAntibodyCross-linking agentReceptor protein-tyrosine kinase erbB-2 cross-linking agent0—
GancotamabPhase 2Merrimack PharmaceuticalsAntibodyBinding agentReceptor protein-tyrosine kinase erbB-2 binding agent0—
MDX-210Phase 2—OtherCross-linking agentReceptor protein-tyrosine kinase erbB-2 cross-linking agent0—
MubritinibPhase 2Takeda Pharmaceuticals USASmall moleculeInhibitor—0—
Trastuzumab botidotinPhase 2—Antibody-drug conjugateBinding agentReceptor tyrosine-protein kinase erbB-2 binding agent0—
VarlitinibPhase 2—Small moleculeInhibitor—0—
AC-480Phase 1Daiichi SankyoSmall moleculeInhibitor—0—
AV-412 free basePhase 1LG ChemSmall moleculeInhibitor—0—
CUDC-101Phase 1Curis, Inc.Small moleculeInhibitor—0—
JNJ-26483327Phase 1Johnson & JohnsonSmall moleculeInhibitor—0—
S-222611Phase 1—OtherInhibitor—0—
TAK-285Phase 1Takeda Pharmaceuticals USASmall moleculeInhibitor—0—
TuxobertinibPhase 1Black Diamond Therapeutics, Inc.Small moleculeNegative allosteric modulatorReceptor protein-tyrosine kinase erbB-2 negative allosteric modulator0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 88 in all, from ClinicalTrials.gov.
HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric CancerTrastuzumabPhase 2Not yet recruitingShanghai Zhongshan Hospital2026-11-17
HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal CancersPertuzumab, TrastuzumabPhase 2Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology2026-11-16
A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer PatientsTrastuzumab, Trastuzumab deruxtecanPhase 2Not yet recruitingCentre Leon Berard2026-11-13
Induction Trastuzumab Rezetecan Followed by Maintenance Dalpiciclib and Endocrine Therapy as First-line Treatment of HR+/HER2 Low mBCTrastuzumabPhase 2Not yet recruitingHarbin Medical University2026-11-13
Neoadjuvant Trastuzumab, Pertuzumab and Zongertinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-5 StudyPertuzumab, TrastuzumabPhase 1Not yet recruitingThe Netherlands Cancer Institute2026-11-10
Trastuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF MutationTrastuzumabPhase 2Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine2026-11-09
3D Versus 2D Strain Echocardiography for Early Detection of Cardiotoxicity During Cancer TherapyTrastuzumab—RecruitingRegion Skane2026-11-04
Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJTrastuzumabPhase 2Not yet recruitingFudan University2026-11-03
Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)Trastuzumab deruxtecanPhase 2Not yet recruitingAzienda Ospedaliero-Universitaria Careggi2026-10-29
A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)ZanidatamabPhase 1Not yet recruitingM.D. Anderson Cancer Center2026-10-28
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerPyrotinibPhase 3Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2026-10-23
Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerDisitamab vedotinPhase 2Not yet recruitingTianjin Medical University Second Hospital2026-10-16
Comparative Study of QL1209 and Perjeta® in Healthy Male ParticipantsPertuzumabPhase 1Not yet recruitingQilu Pharmaceutical Co., Ltd.2026-10-06
Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast CancerPertuzumabPhase 2Not yet recruitingHebei Medical University Fourth Hospital2026-10-05
Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerPertuzumab, Trastuzumab emtansine—RecruitingFundación Santa Fe de Bogota2026-10-02
SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete ResponsePertuzumabPhase 2Not yet recruitingFudan University2026-10-02
DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder CancerDisitamab vedotinPhase 1Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2026-10-01
HER2-positive Breast Cancer Without Intravenous Neoadjuvant TherapyPertuzumabPhase 2Not yet recruitingThe First Affiliated Hospital with Nanjing Medical University2026-09-30
Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract TumorsZanidatamabPhase 2Not yet recruitingAnhui Provincial Hospital2026-09-25
A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXdPyrotinib, Trastuzumab deruxtecanPhase 2Not yet recruitingFujian Medical University2026-09-23
Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab DeruxtecanTrastuzumab deruxtecanPhase 3Not yet recruitingMario Negri Institute for Pharmacological Research2026-09-18
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerTrastuzumab deruxtecan, Trastuzumab emtansinePhase 2Not yet recruitingFudan University2026-09-17
Pyrotinib for HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and PertuzumabPertuzumab, Pyrotinib—Active, not recruitingBeijing 302 Hospital2026-09-09
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBCPyrotinibPhase 3RecruitingShanghai Jiao Tong University School of Medicine2026-09-01
SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast CancerPyrotinibPhase 2Not yet recruitingFirst Affiliated Hospital of Zhejiang University2026-08-26
A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG FailureDisitamab vedotinPhase 1Not yet recruitingXiangya Hospital of Central South University2026-08-25
Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast CancerTrastuzumab deruxtecanPhase 1 / Phase 2Not yet recruitingThe Methodist Hospital Research Institute2026-08-25
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEAZanidatamab—Not yet recruitingJazz Pharmaceuticals2026-08-24
A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast CancerTrastuzumab deruxtecanNot applicableNot yet recruitingShuangyue Liu2026-08-24
Tucatinib Continuation StudyTucatinibPhase 4Not yet recruitingPfizer2026-08-17
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerPyrotinibPhase 2Not yet recruitingFujian Cancer Hospital2026-08-14
Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder CancerDisitamab vedotinPhase 2 / Phase 3Not yet recruitingTianjin Medical University Second Hospital2026-08-10
Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerZanidatamabPhase 3Not yet recruitingUNICANCER2026-08-04
A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland CarcinomaDisitamab vedotinPhase 2Not yet recruitingWest China Hospital2026-08-03
Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNeratinibPhase 2Not yet recruitingUniversity of California, San Diego2026-07-27
SMP-656 for HER2-Positive Advanced Breast CancerTrastuzumab deruxtecanPhase 2RecruitingChengdu SciMount Pharmatech Co., Ltd.2026-07-24
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )Disitamab vedotinPhase 2Not yet recruitingPeking University First Hospital2026-07-22
Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerDisitamab vedotinPhase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2026-07-21
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailurePyrotinibPhase 1 / Phase 2RecruitingTianjin Medical University Cancer Institute and Hospital2026-07-16
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBCDisitamab vedotinPhase 3RecruitingZhiquan Hu2026-07-09
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label StudyZanidatamabPhase 2Not yet recruitingZhifeng Zhao, PhD2026-07-06
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerTrastuzumab emtansinePhase 3RecruitingGeneQuantum Healthcare (Suzhou) Co., Ltd.2026-06-29
Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerAfatinib, PyrotinibPhase 2 / Phase 3Not yet recruitingPeking University Cancer Hospital & Institute2026-06-17
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard TherapyZanidatamabPhase 2Not yet recruitingHaihua Yuan2026-06-08
Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer OrganoidsTrastuzumab emtansine—RecruitingGuangzhou Institute of Respiratory Disease2026-05-28
A Clinical Study of SYS6023 Combination Therapy for Advanced Breast CancerKN-026Phase 2RecruitingCSPC Megalith Biopharmaceutical Co.,Ltd.2026-05-19
GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World SettingTucatinib, Trastuzumab emtansine—RecruitingFondazione Oncotech2026-05-13
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisTrastuzumab emtansinePhase 3RecruitingSWOG Cancer Research Network2026-05-11
A Real-World Study on the Impact of Different Adjuvant Treatment Regimens on Prognosis in Non-pCR Patients With HER2-Positive Breast Cancer After Neoadjuvant TherapyTrastuzumab emtansine—Not yet recruitingHebei Medical University Fourth Hospital2026-04-20
Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast CancerTucatinib, ZanidatamabPhase 1 / Phase 2Not yet recruitingMedSIR2026-03-27
Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal CancerZanidatamabPhase 1 / Phase 2Not yet recruitingUniversitaire Ziekenhuizen KU Leuven2026-03-17
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerKN-026Phase 3RecruitingShanghai JMT-Bio Inc.2026-03-02
De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast CancerTrastuzumab emtansinePhase 2Active, not recruitingNational Medical Research Radiological Centre of the Ministry of Health of Russia2026-02-19
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveTucatinibPhase 2 / Phase 3RecruitingHoffmann-La Roche2026-02-17
Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerNeratinibPhase 2Not yet recruitingXijing Hospital2026-01-12
A Study of KN026-based Combination Therapy in HER2-positive Gastric CancerKN-026Phase 2 / Phase 3Not yet recruitingShanghai JMT-Bio Inc.2026-01-12
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerTucatinibEarly phase 1RecruitingM.D. Anderson Cancer Center2026-01-06
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast CancerTucatinibPhase 2RecruitingInstitut Curie2025-09-25
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsAfatinibPhase 3RecruitingArriVent BioPharma, Inc.2025-09-22
RT for Adenocarcinoma/Adenosquamous CarcinomaNeratinibPhase 1 / Phase 2Active, not recruitingPeking Union Medical College Hospital2025-09-04
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain MetastasisNeratinib, LapatinibPhase 2RecruitingFudan University2025-09-03
Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World StudyNeratinib—Not yet recruitingHebei Medical University Fourth Hospital2025-06-13
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell CarcinomaAfatinibPhase 1 / Phase 2Active, not recruitingWest China Hospital2025-06-08
JSKN003 Combined Treatment of HER2-positive Gastric CancerKN-026Phase 2Not yet recruitingShanghai JMT-Bio Inc.2025-05-31
Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With TucatinibTucatinibNot applicableRecruitingDuke University2025-05-21
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer PatientsNeratinibNot applicableRecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2025-03-24
A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.Tucatinib—RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences2025-02-21
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted TherapyMargetuximab, Neratinib, LapatinibEarly phase 1RecruitingVanderbilt-Ingram Cancer Center2025-02-14
Using Tumor Models to Determine TreatmentsNeratinibPhase 2RecruitingUniversity Health Network, Toronto2025-02-06
FHND9041 Versus Afatinib for Non-small Cell Lung CancerAfatinibPhase 3Enrolling by invitationJiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.2025-01-06
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaAfatinibPhase 1 / Phase 2RecruitingWest China Hospital2024-12-31
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerKN-026Phase 3Active, not recruitingShanghai JMT-Bio Inc.2024-12-24
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLCAfatinibPhase 2RecruitingShandong Public Health Clinical Center2024-11-29
Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)AfatinibPhase 1 / Phase 2RecruitingFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau2024-10-18
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyAfatinibPhase 3RecruitingRegion Skane2024-07-03
A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast CancerHEMAY-022, LapatinibPhase 3RecruitingTianjin Hemay Pharmaceutical Co., Ltd2024-03-15
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast CancerAnvatabart opadotinPhase 2RecruitingLaura Huppert, MD, BA2024-01-25
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GCKN-026Phase 2RecruitingPeking University2023-09-05
KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary CarcinomaKN-026Phase 2Not yet recruitingPeking University Cancer Hospital & Institute2023-08-14
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.KN-026Phase 3RecruitingShanghai JMT-Bio Inc.2023-05-01
Antineoplastic Drugs in Elderly PatientsLapatinib—RecruitingShandong University2022-07-20
MARGetuximab Or Trastuzumab (MARGOT)MargetuximabPhase 2Active, not recruitingDana-Farber Cancer Institute2020-06-11
Implantable Microdevice In Primary Brain TumorsLapatinibEarly phase 1RecruitingOliver Jonas2019-10-23
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerSapitinibPhase 2Active, not recruitingUNICANCER2014-11-24
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentLapatinibPhase 2RecruitingCentre Leon Berard2014-01-07
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by SurgeryLapatinibPhase 1Active, not recruitingNational Cancer Institute (NCI)2013-09-20
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast CancerLapatinibPhase 2Active, not recruitingCity of Hope Medical Center2011-01-10
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerTrastuzumab duocarmazinePhase 2RecruitingQuantumLeap Healthcare Collaborative2010-01-05

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Non-small cell lung carcinoma
0.78
Cancer
0.78
Breast carcinoma
0.70
Gastric adenocarcinoma
0.69
Neoplasm
0.68
Lung adenocarcinoma
0.64
HER2 positive breast carcinoma
0.62
Breast neoplasm
0.62
Urinary bladder carcinoma
0.61

Genes and Related Targets

Complexes and families that share a gene with this target
Genes
ERBB2

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1824, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P04626, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.